Daniel Handayan, MD
Addiction Medicine · Victoria, TXNPI 1194178319
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 35.0% of the total. 2025 is the largest year on record at $215, more than ten times the $19 reported in 2021. That places this record below the midpoint for addiction medicine clinicians in TX, where the typical reported total is $461.
Across 11 payments — averaging $41.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$161
- La Jolla Pharmaceutical Company$125
- AstraZeneca$72
- Indivior Inc.$47
- Alkermes, Inc.$22
- Pfizer$19
- plus $14 from 1 others
Across 13 payments — averaging $4156.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$30K
- Teva Pharmaceuticals USA, Inc.$24K
What the payments were for
- Food & beverage$461100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $161 |
| La Jolla Pharmaceutical Company | 1 | $125 |
| AstraZeneca | 2 | $72 |
| Indivior Inc. | 2 | $47 |
| Alkermes, Inc. | 1 | $22 |
| Pfizer | 1 | $19 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$461 in reported general payments places this provider in the 50th percentile of 42 addiction medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 59 | $8,127 |
| Pregabalin | 13 | $638 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $341 |
| Zolpidem Tartrate | 25 | $200 |
| Gabapentin | 12 | $196 |
| Clonazepam | 12 | $170 |
| Tramadol Hcl | 20 | $109 |
| Atorvastatin Calcium | 11 | $63 |
| Alprazolam | 11 | $53 |
| Amlodipine Besylate | 12 | $41 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Victoria
- Thomas KostenHouston$85K
- Carroll ThornburgEl Paso$33K
- Gloria MaguadogHouston$14K
- Charles IrwinDallas$11K
- Rany CherianBryan$6K
- Bo AllaireBellaire$6K
- James LaiHouston$6K
- Andre ChenRound Rock$4K
- Jeffrey ButtsBoerne$4K
- Michael SprintzHouston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.